Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Mar;7(Suppl 1):S28-S33.
doi: 10.1016/j.afos.2021.03.002. Epub 2021 Mar 30.

Sarcopenia and mortality in cancer: A meta-analysis

Affiliations

Sarcopenia and mortality in cancer: A meta-analysis

Philip Chun-Ming Au et al. Osteoporos Sarcopenia. 2021 Mar.

Abstract

Objectives: The aim of this meta-analysis is to comprehensively evaluate the effects of lean mass on all-cause mortality across different cancer types.

Methods: This is a meta-analysis. Cohort studies on lean mass and mortality published before December 20, 2017 were obtained by systematic search on PubMed, Cochrane Library, and Embase. Inclusion criteria were cohort studies reporting lean mass measurements by dual-energy X-ray absorptiometry, bioimpedance analysis or computed tomography, and with all-cause mortality as the study outcome. Exclusion criteria were studies using muscle mass surrogates, anthropometric measurement of muscle, rate of change in muscle mass, and sarcopenia defined by composite criteria. Hazard ratios (HRs) and 95% confidence intervals (CIs) of low/reduced lean mass on cancer mortality were pooled with a random-effects model. Subgroup analysis stratifying studies according to cancer type and measurement index was performed.

Results: Altogether 100 studies evaluated the association between lean mass and cancer mortality. The overall pooled HR on cancer mortality was 1.41 (95% CI, 1.24 to 1.59) for every standard deviation decrease in lean mass and 1.69 (95% CI, 1.56 to 1.83) for patients with sarcopenia (binary cutoffs). Overall mortality was also significantly associated with sarcopenia in across various cancer types, except for hematopoietic, breast, ovarian and endometrial, and prostate cancer.

Conclusions: The robust association of decreased lean mass with increased mortality further justified the importance of developing clinical guidelines for managing sarcopenia in cancer patients. Public health initiatives aiming at promoting awareness of muscle health in susceptible individuals are urgently needed.

Keywords: Cancer; Lean mass; Sarcopenia.

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests.

Figures

Fig. 1
Fig. 1
The meta-analysis of reduced lean mass (per SD decrease) on mortality. Keys: Full model refers to analysis adjusted for any of the followings (either alone or in combination): age, sex, ethnicity, height, weight or body mass index, and other confounding factors. HR, hazard ratio; CI, confidence interval; SD, standard deviation.
Fig. 2
Fig. 2
The meta-analysis of low lean mass on mortality. Keys: Full model refers to analysis adjusted for any of the followings (either alone or in combination): age, sex, ethnicity, height, weight or body mass index, and other confounding factors. HR, hazard ratio; CI, confidence interval; SD, standard deviation.

References

    1. van Vugt J.L.A., Buettner S., Levolger S., Coebergh van den Braak R.R.J., Suker M., Gaspersz M.P. Low skeletal muscle mass is associated with increased hospital expenditure in patients undergoing cancer surgery of the alimentary tract. PloS One. 2017;12 - PMC - PubMed
    1. Arthur S.T., Van Doren B.A., Roy D., Noone J.M., Zacherle E., Blanchette C.M. Cachexia among US cancer patients. J Med Econ. 2016;19:874–880. - PubMed
    1. Fearon K., Strasser F., Anker S.D., Bosaeus I., Bruera E., Fainsinger R.L. Definition and classification of cancer cachexia: an international consensus. Lancet Oncol. 2011;12:489–495. - PubMed
    1. Hilmi M., Jouinot A., Burns R., Pigneur F., Mounier R., Gondin J. Body composition and sarcopenia: the next-generation of personalized oncology and pharmacology? Pharmacol Ther. 2019;196:135–159. - PubMed
    1. Prado C.M., Baracos V.E., McCargar L.J., Mourtzakis M., Mulder K.E., Reiman T. Body composition as an independent determinant of 5-fluorouracil-based chemotherapy toxicity. Clin Canc Res. 2007;13:3264–3268. - PubMed

LinkOut - more resources